Loading...

Zynerba Pharmaceuticals, Inc.

ZYNE•NASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$1.30
$0.03(2.36%)

Zynerba Pharmaceuticals, Inc. (ZYNE) Stock Overview

Explore Zynerba Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for ZYNEStats details for ZYNE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ZYNEAnalyst Recommendations details for ZYNE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

CEO

Mr. Armando Anido MBA

Employees

25

Headquarters

80 West Lancaster Avenue, Devon, PA

Founded

2015

Frequently Asked Questions